Response to targeted therapy in two patients with metastatic melanoma carrying rare : A598_T599insV and V600_K601delinsEBRAF: A598_T599insV and V600_K601delinsE exon 15 mutations: A598_T599insV and V600_K601delinsE

    loading  Checking for direct PDF access through Ovid

Abstract

Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations – BRAF A598_T599insV and V600_K601delinsE – obtaining clinical benefit and a radiological response to inhibitors directed against the mitogen-activated protein kinase pathway. This highlights the importance of using tests that detect both V600E/K and non-V600E/K BRAF mutations to keep open the possibility of treatment with targeted therapy in patients with uncommon, yet potentially actionable, BRAF exon 15 mutations.

Related Topics

    loading  Loading Related Articles